Introduction
Chronic obstructive pulmonary disease (COPD) is an umbrella term used to describe progressive lung diseases including emphysema and chronic bronchitis. COPD patients often experience dyspnea, cough, sputum and chest tightness which may worsen during acute exacerbation of COPD (AECOPD). 
Aim
Study objective was to evaluate the effects of a new ACT technology (Simeox, Physio-Assist, France) in hospitalized COPD patients suffering of chest congestion compared to manual physiotherapy.
Methods
10 COPD patients (FEV1>20%) with AECOPD who reported excessive mucus congestion and difficulties to clear airways despite bronchodilator therapy were treated 5 days (2 sessions of 20-min/day) during hospitalization with either Simeox technology or manual physiotherapy (5 patients in each group).
Simeox device generates a vibratory pneumatic signal in the bronchial tree during relaxed exhalation by disseminating a succession of very short air depressions of constant volume at a frequency similar to that of the vibratory cilia of the bronchial epithelium.
By this way, the signal mobilizes mucus in the distal tracts to change its rheology and transport it to the proximal tract for expectoration. Patients were excluded if they had recent pneumothorax, severe cardiac health issues, recent haemoptysis or inability to perform spirometry.
Spirometry, symptoms, CAT score, usability and safety were compared between the 2 groups.
All the patients of device group acquired quickly autonomous usage. No adverse event nor pain was reported.
Improvement of mucus clearance and symptoms were similar between groups.
FEV1(L) improved by +0.15±0.10L (FEV1% +5±2%)
FEV1/FVC increased from 52.5±2.4% to 58.0±12.8% in the device (Simeox) group but remained stable in the manual physiotherapy group.
CAT score improved in the device (Simeox) group only from 20.2±6.4 to 17.0±4.6
Results Age 65±8ys, 7 men and 3 women, 7 with bronchiectasis and 8 had lung crackles, BMI 27.1±6.1kg/m2, Borg scale 4.5±1.8, SpO2 96.3±1.7%, FEV1% 42±19.
Conclusions
These preliminary data suggest safety and additional benefits of Simeox airway clearance technology for COPD with severe chronic bronchitis symptoms or bronchiectasis.
There is a need in further randomised studies including more patients for a longer follow-up. 
Aim and objectives
Study aim was to evaluate the effects of a new ACT in hospitalized COPD patients suffering of chest congestion compared to manual physiotherapy.
Methods 10 COPD patients with AECOPD who reported excessive mucus congestion despite bronchodilator therapy were treated 5 days (2 sessions of 20-min/day) during hospitalization with either ACT device (Simeox, Physio-Assist) or manual physiotherapy (5 patients in each group). This device facilitates mucus clearance by generating successive low-frequency depressions during passive exhalation. Spirometry, symptoms, CAT score, usability and safety were compared between the 2 groups.
Results
Age 65±8ys, 7 men and 3 women, 7 with bronchiectasis and 8 with lung crackles, BMI 27.1±6.1kg/m2, Borg scale 4.5±1.8, FEV1% 42±19. All the patients of device group acquired quickly autonomous usage. No adverse event nor pain was reported. Improvement of mucus clearance and symptoms were similar between groups. FEV1(L) improved by +0.15±0.10L (FEV1% +5±2%) and FEV1/FVC increased from 52.5±2.4 to 58.0±12.8% in the device group but remained stable in the manual physiotherapy group. CAT score improved in the device group only from 20.2±6.4 to 17.0±4.6.
Conclusions
These preliminary data suggest safety and additional benefits of low-frequency airway clearance technology for COPD with severe chronic bronchitis symptoms or bronchiectasis. There is a need in further randomised studies including more patients for a longer follow-up.
